← Back to Clinical Trials
Recruiting NCT06995014

NCT06995014 Retrieval-based Word Learning in Developmental Language Disorder: Adaptive Retrieval Schedule

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06995014
Status Recruiting
Phase
Sponsor Purdue University
Condition Developmental Language Disorder
Study Type INTERVENTIONAL
Enrollment 32 participants
Start Date 2024-08-15
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 48 Months
Max Age 71 Months
Study Type INTERVENTIONAL
Interventions
Retrieval-based word learning: Standard retrieval practice scheduleRetrieval-based word learning: Adaptive retrieval practice schedule

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 32 participants in total. It began in 2024-08-15 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Children with developmental language disorder (DLD; also referred to as specific language impairment) experience a significant deficit in language ability that is longstanding and harmful to the children's academic, social, and eventual economic wellbeing. Word learning is one of the principal weaknesses in these children. This project focuses on the word learning abilities of four- and five-year-old children with DLD. The goal of the project is to determine whether special benefits accrue when these children must frequently recall newly introduced words during the course of learning. In the current study, the investigators compare a "standard" repeated spaced retrieval schedule, with fixed spacing between hearing a word and attempting to retrieve it, to an "adaptive" repeated spaced retrieval schedule in which opportunities to retrieve a given word are tailored to the individual child's current knowledge state. The goal of the study is to determine whether the adaptive schedule can increase children's absolute levels of learning while maintaining the advantages of repeated spaced retrieval.

Eligibility Criteria

Inclusion Criteria: * a significant deficit in language ability (language test score below cutoff for best sensitivity/specificity) or documented age-appropriate language ability. * normal hearing. * no evidence of neurological damage or disease. * scores on tests of nonverbal intelligence above the intellectual disability range * not within Autistic range on Autism screening test * native English speaker (can be bilingual) Exclusion Criteria: * failed hearing screening * known neurological damage or disease * scores on tests of nonverbal intelligence below the intellectual disability range (standard score less than 75) * autism spectrum disorder * non-native English speaker

Contact & Investigator

Central Contact

Patricia L Deevy, PhD

✉ deevy@purdue.edu

📞 765-496-1821

Principal Investigator

Laurence B Leonard, PhD

PRINCIPAL INVESTIGATOR

Purdue University

Frequently Asked Questions

Who can join the NCT06995014 clinical trial?

This trial is open to participants of all sexes, aged 48 Months or older, up to 71 Months, studying Developmental Language Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06995014 currently recruiting?

Yes, NCT06995014 is actively recruiting participants. Contact the research team at deevy@purdue.edu for enrollment information.

Where is the NCT06995014 trial being conducted?

This trial is being conducted at West Lafayette, United States.

Who is sponsoring the NCT06995014 clinical trial?

NCT06995014 is sponsored by Purdue University. The principal investigator is Laurence B Leonard, PhD at Purdue University. The trial plans to enroll 32 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology